tbuckley/cabot-search huggingface dataset:
35207 Cost analysis of seborrheic dermatitis treatment for patients in a dermatology center in Bogota, Colombia
Authors: David A. Castillo Molina, Maria J. Sanchez-Zapata, Jesus D. Fierro-Lozada, Cris Madeley Millan-Puerto, Luisa Fernanda Camacho-Lazaro, Sara Muñoz-Ordoñez, Diego Mauricio Martinez-Zuñiga
Journal: Journal of the American Academy of Dermatology (2022)
32329 Assessing the utility of Fontana-Masson and MART-1 stains in evaluating skin pigmentary changes induced by ultraviolet radiation and visible light
Authors: Marissa S. Ceresnie, Indermeet Kohli, Ben J. Friedman, Henry W. Lim, Iltefat H. Hamzavi
Journal: Journal of the American Academy of Dermatology (2022)
34762 Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study
Authors: Michael Schenker, Mikhail Klochikhin, Ase Bratland, Dmitry Kirtbaya, Alexander Guminski, Marcin Dzienis, Chrysalyne Schmults, Joy Y. Ge, Jianda Yuan, Jenny Lee
Journal: Journal of the American Academy of Dermatology (2022)
32888 Primary cutaneous B-cell lymphoma treated with systemic rituximab
Authors: Jake Besch-Stokes, Puneet Bhullar, Pranav Puri, Blake Boudreaux, Collin Costello, William Rule, Allison Rosenthal, David J. DiCaudo, Mark R. Pittelkow, Aaron Mangold
Journal: Journal of the American Academy of Dermatology (2022)
31243 Age requirements for regarding indoor UV tanning in Colorado
Authors: Melissa R. Laughter, Jaclyn B. Anderson, Darya Sinkevich, Jarett D. Anderson, Ronald A. Yang, Neil Box, Yadira Caraveo, Geoff Lim, Robert Dellavalle, Mona Sadeghpour
Journal: Journal of the American Academy of Dermatology (2022)
32922 Intralesional rituximab for indolent primary cutaneous B-cell lymphoma
Authors: Jake Besch-Stokes, Puneet Bhullar, Pranav Puri, Blake Boudreaux, Collin Costello, William Rule, Allison Rosenthal, David J. DiCaudo, Mark R. Pittelkow, Aaron Mangold
Journal: Journal of the American Academy of Dermatology (2022)
34986 Optimizing representation of skin of color in preclinical medical curricula at two Mayo Medical School campuses
Authors: Rewan Abdelwahab, Olayemi Sokumbi, Derrick Lewis, Ewoma Ogbaudu, Johanny Lopez Dominguez, Amit Shah, Amy Seegmiller Renner, Joseph J. Malesewski, Taylor Thomas, Sarah J. Atunah-Jay
Journal: Journal of the American Academy of Dermatology (2022)
34086 Rapid response of truncal acne with oral sarecycline
Authors: Angela Moore
Journal: Journal of the American Academy of Dermatology (2022)

Truncal acne affects 60-70% of acne patients and larger surface areas than facial acne. Topical treatment application becomes more difficult. Oral sarecycline, a narrow-spectrum, third-generation tetracycline-class antibiotic, is FDA-approved for moderate-to-severe acne vulgaris in patients aged 9 and older. Sarecycline's potent anti-inflammatory activity, activity against Cutibacterium acnes and clinically relevant Gram-positive bacteria, but reduced activity against enteric Gram-negative bacteria, may contribute to its favorable safety and tolerability profile. We present a series of 10 patients with moderate-to-severe acne vulgaris on the trunk (chest and back) treated with sarecycline monotherapy once daily for 3 months, and assessed inflammatory lesion counts, percent reduction, and IGA scores of truncal acne, with objective photographs at baseline and week 12. Of these 10 patients, 50% were male and 50% were female. Thirty percent were Hispanic and 70% were non-Hispanic. At baseline, the patients presented with an average of 74.4 inflammatory lesions on the trunk, with 40% IGA 3 (moderate) and 60% IGA 4 (severe). Reduction in truncal inflammatory lesions by 52% to an average of 40.9 lesions (P = .0064) was observed as early as week 3, and by 90% to an average of 24.8 lesions (P = .0003) by week 12. At week 12, 60% had a 2-point reduction and IGA of 0 (clear) or 1 (almost clear). No side effects, including nausea, diarrhea, esophagitis, pseudotumor cerebri, blurry or double vision, dizziness, vertigo, or blue-gray pigmentation were observed. This case series objectively supports previous observation of significant IGA improvement in truncal acne in Phase 3 clinical trials.
32696 Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
Authors: Lea Hoisnard, Pr Sébastien Maury, Pr Matthieu Mahévas, Khalil El Karoui, Lydia Roy, José L. Cohen, Pr Aurélien Amiot, Pr Pascal Claudepierre, Pr Philippe Grimbert, Pr Emilie Sbidian
Journal: Journal of the American Academy of Dermatology (2022)
33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Authors: Mark Lebwohl, Kamran Ghoreschi, Bruce Strober, Kilian Eyerich, Jennifer Cather, Maggie Wang, Christopher Cioffi, Delphine Deherder, Fabienne Staelens, Natalie Nunez Gomez, Luis Puig
Journal: Journal of the American Academy of Dermatology (2022)
34320 Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis
Authors: David Rosmarin, Mark Lebwohl, Steven R. Feldman, Petra Staubach-Renz, Leah Davis, Krista Wixted, Cynthia Madden, Natalie Nunez Gomez, Andreas Pinter
Journal: Journal of the American Academy of Dermatology (2022)
35062 Onychomycosis and irrational drug use, a growing public health problem
Authors: Nora Ximena Ugalde Trejo, Karla Paola Delgado Moreno, Marielva Castro González, Estefania Boland Rodríguez, Salomón Pineda Benítez, Enrique Villarreal Ríos, María Fernanda Ugalde Trejo, María Alcocer León, Alessandra Miranda Aguirre, Abraham Benjamín Alfaro Sánchez
Journal: Journal of the American Academy of Dermatology (2022)
31057 Ixekizumab treatment response: Consistency over time and at each visit in psoriatic arthritis
Authors: Joseph F. Merola, Laura C. Coates, David M. Sandoval, Rebecca Bolce, So Young Park, Alyssa Garrelts, Keri Brooke Stenger, Aubrey Trevelin Sprabery, Arthur Kavanaugh
Journal: Journal of the American Academy of Dermatology (2022)
35171 Malignant melanoma cases associated with IL-23 inhibitors: Pharmacovigilance analysis of real-world evidence in the Food and Drug Administration Adverse Event Reporting System (FAERS) from the RADAR (Research on Adverse Drug events And Reports) program
Authors: Negar Kahen, Yasmeen Ali, Dennis P. West, Beatrice Nardone
Journal: Journal of the American Academy of Dermatology (2022)
33124 Severe infections, confirmed extended major adverse cardiovascular events, and malignancies over 5 years of treatment with tildrakizumab in terms of number needed to harm: Pooled analyses from the reSURFACE 1 and reSURFACE 2 phase 3 trials
Authors: Andreas Pinter, Jean-Philippe Lacour, Alexander Egeberg
Journal: Journal of the American Academy of Dermatology (2022)
33702 The role of dermatologists on the diagnosis of leukemias such as blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Authors: Nerea Mohino-Farré, Laia Pastor-Jané, Josep Pujol-Montcusi, Anna Vicent, Julieta Landeyro, Anna Sánchez-Puigdollers, Miquel Just, Clara Martin, Maria del Mar Cordellat, Pilar Turégano
Journal: Journal of the American Academy of Dermatology (2022)
33960 Real world evidence cohort of patients switched to guselkumab after ustekinumab
Authors: Mar Llamas-Velasco, Luisa Martos-Cabrera, Raquel Sampedro, Raquel Rivera, Pedro Herranz, Pablo de la Cueva, Diana Ruiz-Genao, Sonsoles Berenguer-Ruiz, Gastón Roustan, Esteban Daudén
Journal: Journal of the American Academy of Dermatology (2022)
34242 A comparison of acne products advertised on Instagram to American Academy of Dermatology evidence-based guidelines
Authors: Anthony Concilla, Chandler W. Rundle, Michelle Militello, Kayd J. Pulsipher, Taylor Harp, Mindy Szeto, Colby L. Presley, Larissa Rodriguez-Homs, Olivia Jew, Robert P. Dellavalle
Journal: Journal of the American Academy of Dermatology (2022)
33171 Real-world data study in health care costs from adults with psoriasis who initiated treatment with apremilast or biologics
Authors: Jashin J. Wu, Ann (Ching An) Wang, Greeta Jobson, David Davidson, Samaneh Kalirai, Julia (Ning) Zhu, Manasi Suryavanshi, Mayank Mittal, Vardhaman Patel, Lauren Seigel
Journal: Journal of the American Academy of Dermatology (2022)
34574 Systemic medication treatment patterns in adults with atopic dermatitis (AD): Results from the European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD)
Authors: Marjolein de Bruin-Weller, Annalisa Patrizi, Silvia Mariel Ferrucci
Journal: Journal of the American Academy of Dermatology (2022)
34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years
Authors: Jacob P. Thyssen, Andrew Blauvelt, Benjamin Lockshin, Ryszard Galus, Charles Lynde, Jing Xiao, Noah A. Levit, Ainara Rodríguez Marco, Arsalan Shabbir
Journal: Journal of the American Academy of Dermatology (2022)
32932 Evaluation of analytical alterations produced during the monitoring of patients with severe psoriasis undergoing treatment with ustekinumab, secukinumab and ixekizumab
Authors: Ana Medina-Fernández, Jorge Alonso Suárez-Pérez, Enrique Herrera-Acosta, Pilar Luque-Varela, Enrique Herrera-Ceballos
Journal: Journal of the American Academy of Dermatology (2022)
33257 Secukinumab effects on cardiovascular risk factors in patients with psoriasis, psoriatic arthritis and axial spondyloarthritis: Results from post hoc analyses of pooled data from 19 phase 3/4 clinical studies
Authors: Joseph F. Merola, Iain B. McInnes, Atul A. Deodhar
Journal: Journal of the American Academy of Dermatology (2022)
34891 A systematic narrative review of skin cancer related knowledge, attitudes, and practices among beachgoers
Authors: Vinayak K. Nahar, Amanda H. Wilkerson, Ross L. Pearlman, Emily K. Cobb, Isabella Aldana, Natalie Garcia, Arjun Pandya, Alexis Hilts, Allison R. Cruse
Journal: Journal of the American Academy of Dermatology (2022)
32746 The clinical utility of teledermatology in triaging and diagnosing skin malignancies: A series of three cases
Authors: Kimberly A. Sable, Allison E. Nackers, Sarah A. Korger, Daniel D. Bennett, Yaohui G. Xu, Molly A. Hinshaw, Apple A. Bodemer, Anne E. Rosin
Journal: Journal of the American Academy of Dermatology (2022)
34615 Tapinarof cream 1% once daily for plaque psoriasis: Dermatology Life Quality Index and local tolerability scores from a long-term extension trial
Authors: April W. Armstrong, Seemal R. Desai, Melinda Gooderham, David S. Rubenstein, Philip M. Brown, Anna M. Tallman, Leon Kircik
Journal: Journal of the American Academy of Dermatology (2022)
33911 Hidradenitis suppurativa secondary to nivolumab
Authors: Noura Ayoubi, Caroline A. Gerhardt, Kerry Hennessy, Sairekha Ravichandran, Nupur Patel, Erfon Ekhlasi, Nora Vera, George Glinos, Alejandro Rabionet, Leigh Hatch, Lilia Correa-Selm
Journal: Journal of the American Academy of Dermatology (2022)
33307 Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis
Authors: Sonja Ständer, Gil Yosipovitch, Jean-Philippe Lacour, Franz J. Legat, Carle Paul, Adam Reich, Kamel Chaouche, Faiz Ahmad, Warren Winkleman, Christophe Piketty
Journal: Journal of the American Academy of Dermatology (2022)
34952 Efficacy and safety of 2 doses of onabotulinumtoxin A for the treatment of masseter muscle prominence: 6-month results from a randomized, phase 2b placebo-controlled study
Authors: Sabrina Fabi, Derek Jones, Brian Biesman, Alexander Rivkin, Julia Garcia, Tanya Brandstetter, Grace Pan, Beta Bowen, Elisabeth Lee, Mitchell F. Brin
Journal: Journal of the American Academy of Dermatology (2022)
33110 An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis
Authors: Joseph F. Merola, Yi-Hsuan Liu, Ya-Wen Yang, Megan Miller, May Shawi, Daphne Chan, Saakshi Khattri, Laura Savage, Chenglong Han
Journal: Journal of the American Academy of Dermatology (2022)
33496 Multidisciplinary atopic dermatitis program: A novel approach to managing difficult-to-control atopic dermatitis patients
Authors: Safiyyah Bhatti, Alexis Tracy, Lauren Loop, Norma Villapando, Alyssa Wu, Pharm D, Margaret M. Appia, Lawrence Eichenfield, Bob Geng
Journal: Journal of the American Academy of Dermatology (2022)
31786 Maintenance effect of a once a week regimen of a selenium disulfide-based shampoo following a 2-week treatment with a topical corticosteroid/salicylic acid product in moderate to severe scalp seborrheic dermatitis
Authors: Philippe Massiot, Corinne Chagnoleau, Leila Kanoun-Copy, Florence Pouradier, Geneviève Loussouarn, Catheine Queille-Roussel, Delphine Kerob
Journal: Journal of the American Academy of Dermatology (2022)
33407 Accuracy of clinical-dermatoscopic versus dermatopathologic diagnosis of melanoma and nonmelanoma skin cancer
Authors: Claudio de Lelis Filgueiras de Souza, Guilherme Gonçalves Nascimento, João Paulo de Oliveira, Júlia Carvalho Giannini, Roberta Bessa de Veloso Silva, Adilson da Costa
Journal: Journal of the American Academy of Dermatology (2022)
34405 Host and primary tumor factors for the development of multiple cutaneous squamous cell carcinomas
Authors: Isabelle H. Moseley, Erica Lin, Rachel Lim, Megan Hoang, Navya Baranwal, Leslie Robinson-Bostom, Tiffany Libby, Oliver Wisco, Abrar Qureshi, Eunyoung Cho
Journal: Journal of the American Academy of Dermatology (2022)
34021 Family impact of moderate-to-severe atopic dermatitis in children aged &lt;12 years: Results from 732 patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
Authors: Marjolein de Bruin-Weller, Marie L.A. Schuttelaar, Charles W. Lynde, Nelson Augusto Rosario Filho, Chunyuan Liu, Brad Shumel, Annie Zhang
Journal: Journal of the American Academy of Dermatology (2022)
33025 Stability of PASI &lt;3 response to tildrakizumab through 5 years: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials
Authors: Diamant Thaçi, Stefano Piaserico, Kristian Gaarn Du Jardin
Journal: Journal of the American Academy of Dermatology (2022)
33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
Authors: Linda Stein Gold, Jerry Bagel, James Del Rosso, Lawrence J. Green, Mark Lebwohl, Leon H. Kircik, Amy Feng, Scott Snyder, Robert C. Higham, Patrick Burnett, David R. Berk
Journal: Journal of the American Academy of Dermatology (2022)
33673 Top dermatology influencers on Twitter: Analysis of content and academic impact
Authors: Mindy D. Szeto, Jadesola T. Olayinka, Kevin Kamel, Austin Hamp, Jarett Anderson, Lori S. Kim, Madeleine G. Yemc, Torunn E. Sivesind, Robert P. Dellavalle
Journal: Journal of the American Academy of Dermatology (2022)
34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab
Authors: Hendrik Schulze-Koops, Atul Deodhar, Reinhard E. Voll, Jan Leipe, Andrew Blauvelt, Craig Leonardi, Effie Pournara, Ivette Alarcon, Weibin Bao, Vivek Trivedi, Philip J. Mease
Journal: Journal of the American Academy of Dermatology (2022)
33456 Generalized congenital myofibromatosis
Authors: Anna Sánchez-Puigdollers, Josep Pujol-Montcusí, Laia Pastor-Jane, Sergio César-Díaz, Mar Albujar, Joan Garcia-Fontgivell, Susana Bel, Nerea Mohino, Pilar Turegano, Ricardo Closa
Journal: Journal of the American Academy of Dermatology (2022)
33298 Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
Authors: Andrew Blauvelt, Richard Langley, Eric Simpson, Richard B. Warren, Antonio Costanzo, Hidehisa Saeki, Darryl Toth, Marie Tauber, Andreas Pinter, Mahreen Ameen, Kristian Reich
Journal: Journal of the American Academy of Dermatology (2022)
32264 Long-term efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in pediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) up to 108 weeks
Authors: A.S. Paller, M.M.B. Seyger, G.A. Magariños
Journal: Journal of the American Academy of Dermatology (2022)
33180 Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial
Authors: Maria K. Hordinsky, Adelaide Hebert, Melinda Gooderham
Journal: Journal of the American Academy of Dermatology (2022)
33270 Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up
Authors: Kim A. Papp, Mark G. Lebwohl, Lluís Puig
Journal: Journal of the American Academy of Dermatology (2022)
33228 Efficiency and survival of guselkumab attending to demographic characteristics and comorbidities in 127 patients with moderate-to-severe psoriasis
Authors: L. Rodriguez-Fernandez-Freire, Ricardo Ruiz-Villaverde, Jose C. Armario-Hita, Fiorella Vasquez, Amalia Perez-Gil, Leandro Martinez-Pilar, Manuel Galan-Gutierrez
Journal: Journal of the American Academy of Dermatology (2022)
32970 Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized phase 2 and phase 3 studies of the first triple-combination drug
Authors: Linda Stein Gold, Leon H. Kircik, Physicians Skin Care, PLLC, Emil A. Tanghetti
Journal: Journal of the American Academy of Dermatology (2022)
32571 Intensive dutasteride mesotherapy protocol (IDMP) with oral minoxidil as an alternative to antiandrogens in AGA. A retrospective analysis of a hair restoration center
Authors: Estefania Boland-RodrÍguez, César Daniel Villarreal-Villarreal, Abraham Benjamín Álfaro-Sánchez
Journal: Journal of the American Academy of Dermatology (2022)
34284 Evaluating the association between poor sleep and myocardial infarction in patients with psoriasis
Authors: Tina Bhutani, Marwa Hakimi
Journal: Journal of the American Academy of Dermatology (2022)

Chronic sleep impairment is a risk factor for cardiovascular (CV) disease and metabolic disorders. The aim of this analysis was to determine whether there is an association between sleep quantity and CV disease in patients with psoriasis. Data from the 2020 National Psoriasis Foundation Annual Survey, a cross sectional study using an online survey of individuals with psoriasis, was used for this analysis. Invitations to participate were emailed to a random-stratified sample of individuals with psoriatic disease.
33183 Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial
Authors: Natasha Mesinkovska, Jerry Shapiro, Brett King
Journal: Journal of the American Academy of Dermatology (2022)
33555 High concentration (15%) vitamin C (ascorbic acid) stabilized in unique aqueous vehicle with feverfew, polyhydroxy acid (PHA) and epigallocatechin gallate (EGCG) provides clinical benefits for hyperpigmentation in a diverse population
Authors: Marisa Dufort, Brenda L. Edison, Neena K. Tierney
Journal: Journal of the American Academy of Dermatology (2022)
33371 Can dermatology practices play a role in combatting vaccine hesitance?
Authors: Charles Dunn, Nicole Vesely, Yasser Faraj
Journal: Journal of the American Academy of Dermatology (2022)

Background: Vaccine hesitancy is common and increasingly relevant in the current medical landscape. Simply based on volume, dermatology practices intersect with the community more than most medical providers. At risk populations for vaccine preventable illnesses are also relatively commonplace in dermatology clinics, as is the practice of injectable therapeutics. Based on these factors, we hypothesize that dermatology clinics have a unique opportunity to positively impact the public health of the population they serve through vaccine administration. Methods: From May until August 2021, 220 patients received a single or two-dose series of the COVID-19 vaccine at their local dermatology clinic as part of a vaccine outreach initiative. A 5-question survey was provided to these patients exploring perspectives, satisfaction, and interest in further vaccinations if offered. Compliance with second dose regimens was also measured. Results: Preliminary data shows high degrees of satisfaction with vaccines administered at the dermatology office. 97% of eligible patients followed through on second dose regimens. "Convenience" and "comfort with the practice" were the two most common listed reasons for vaccine compliance. 88% of patients stated they would receive other vaccines at their dermatology clinic if recommended and available. Conclusion: Based on these data, it appears that Dermatology clinics can positively impact vaccine hesitance and play a role in public health through offering certain vaccines at their facilities. This data could be extrapolated to make an argument for expanded vaccine administration targeted toward conditions salient to everyday dermatology practice (eg, vaccines for human papillomavirus and varicella zoster).
34852 Medication-induced hair texture change: A systematic review
Authors: Celine H. Phong, Gabrielle T. Baker, Melody Esmaeili
Journal: Journal of the American Academy of Dermatology (2022)

Background: Although hair loss is a worrisome side effect of many medications, hair texture changes such as curling, waving, and kinking are also reported by patients but are poorly characterized in the literature. We aim to identify in the scientific evidence all medication classes linked to hair texture changes.
33284 Efficacy of nemolizumab in atopic dermatitis: Rapid impact on EASI and SCORAD components
Authors: Jean-David Bouaziz, Andreas Pinter, Afsaneh Alavi
Journal: Journal of the American Academy of Dermatology (2022)

Background: Nemolizumab is an interleukin 31 receptor inhibitor in phase 3 for atopic dermatitis (AD). Common AD scores SCORing Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) help delineate action of nemolizumab.